mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

 

Press releases

Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma

29.09.2016 by
Eleventa Ltd. (Moscow, Russia), a portfolio company of Maxwell Biotech Venture Fund (MBVF), and its development partner, Oxagen Limited (Abingdon, UK), today announced the completion of patient enrollment in the a Phase 3 clinical study of Timapiprant (formerly OC000459), for treatment of  atopic eosinophilic asthma in adults. Two hundred twelve patients have been enrolled in
Read more
No Comments

NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the treatment of neuropathic pain

28.06.2016 by
Maxwell Biotech Venture Fund’s portfolio company NeuroMax Ltd and its development partner, Aquilus Pharmaceuticals, Inc today announced the start of Phase 1, open label, prospective, safety, tolerability and pharmacokinetics study of AQU-005 for the treatment of chronic neuropathic pain. Recruitment in the clinical study is underway and is expected to enroll up to 24 healthy
Read more
No Comments

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology

01.06.2016 by
Hepatera LLC and it`s development partner MYR GmbH today announced that the results of the first-in-man Phase 1 study in healthy volunteers, and the proof-of-concept Phase 2a study in HBV/HDV co-infected patients were published as two separate “back-to-back” articles in Journal of Hepatology and are available online. «We are pleased that the one of the
Read more
No Comments

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection

28.03.2016 by
Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.  We are looking
Read more
No Comments

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Announces Initiation of a Pilot Clinical Trial Of Myrcludex B In Patients With HDV

02.04.2014 by
Hepatera Ltd. announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund formed with the participation of RVC – Russia’s government fund of venture capital funds. Hepatera was founded in 2011 with the goal
Read more
No Comments

Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Completes Enrollment of Phase IIa clinical trial of Myrcludex B, for HBV

07.03.2014 by
A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. Hepatera is financed by Maxwell Biotech Venture Fund, set up with the participation of RVC – Russia’s government fund of venture capital funds. Hepatera was
Read more
No Comments

Maxwell Biotech Venture Fund’s Portfolio Company Infectex Acquires Exclusive Rights to Qurient’s Tuberculosis Drug Q203

14.02.2014 by
Russian and Korean biotech companies Infectex, Ltd. and Qurient, Ltd. have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurient’s Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan  and Ukraine. Infectex is a portfolio company of Maxwell Biotech Venture Fund, created with the
Read more
No Comments

OncoMax research received “FIRST PRIZE” award at EMUC- 2013

26.11.2013 by
OncoMax presented its research at the 5th European Multidisciplinary Meeting for Urological Cancer (EMUC), which was held on 15-17 November 2013 in Marseille, France. Dr. Ilya Tsimafeyeu, a scientific advisor of OncoMax, has received a special award for the best research “FIRST PRIZE” for his study “FGF- and VEGF-dependent angiogenesis and its targeting”. The main
Read more
No Comments

OncoMax, MetaMax, Osteros Biomedica will take part in the XVII Russian Cancer Congress

11.11.2013 by
From 12 to 14 November 2013, the World Trade Center, Moscow, will host the XVII Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer market. The event will be attended by Skolkovo Biomedical Cluster resident companies, including OncoMax, Metamax and Osteros Biomedica, backed by Maxwell Biotech Venture Fund,
Read more
No Comments

Oncomax and Metamax are Prix Galien Russia 2013 Nominees for “Best Research in Russia”

23.10.2013 by
The 2013 Prix Galien Russia ceremony will take place in Moscow on the 24th of October. A jury of eminent specialists involved in the sphere of Russian and international pharmaceutical research will announce the laureates in three categories: Best Research in Russia, Best Pharmaceutical Agent and Best Biopharmaceutical Product. Laureates of three categories will be
Read more
No Comments

© Maxwell Biotech Group Ltd.

TOP